About Matinas BioPharma (NYSEAMERICAN:MTNB)
Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on identifying and developing antifungal and anti-bacterial therapeutics for the treatment of various infections in the United States. It develops orally delivered therapeutics based on cochleate delivery technology, a proprietary lipid-based drug delivery platform. The company's lead product candidate is MAT2203, an orally-administered cochleate formulation of amphotericin B, a broad spectrum anti-fungal drug, which has completed Phase II clinical study for the treatment of fungal infections. Its lead product candidate also includes MAT2501, an orally administered cochleate formulation of the broad spectrum aminoglycoside antibiotic amikacin that has completed Phase I clinical trials to treat various multidrug-resistant bacteria, including non-tuberculous mycobacterium infections, as well as multidrug-resistant gram negative and intracellular bacterial infections. The company was founded in 2013 and is based in Bedminster, New Jersey.
Industry, Sector and Symbol
Trailing P/E RatioN/A
Forward P/E RatioN/A
Sales & Book Value
Price / SalesN/A
Price / CashN/A
Price / BookN/A
EPS (Most Recent Fiscal Year)N/A
Return on Equity-195.09%
Return on Assets-79.34%
Matinas BioPharma (NYSEAMERICAN:MTNB) Frequently Asked Questions
What is Matinas BioPharma's stock symbol?
Matinas BioPharma trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "MTNB."
How were Matinas BioPharma's earnings last quarter?
Matinas BioPharma Holdings Inc (NYSEAMERICAN:MTNB) posted its quarterly earnings data on Thursday, May, 10th. The company reported ($0.05) EPS for the quarter, missing the consensus estimate of ($0.04) by $0.01. The firm had revenue of $0.03 million for the quarter. Matinas BioPharma had a negative return on equity of 195.09% and a negative net margin of 7,558.92%. View Matinas BioPharma's Earnings History.
When is Matinas BioPharma's next earnings date?
What price target have analysts set for MTNB?
2 brokerages have issued twelve-month price objectives for Matinas BioPharma's shares. Their predictions range from $4.00 to $9.00. On average, they anticipate Matinas BioPharma's share price to reach $6.50 in the next twelve months. View Analyst Ratings for Matinas BioPharma.
Are investors shorting Matinas BioPharma?
Matinas BioPharma saw a increase in short interest during the month of May. As of May 31st, there was short interest totalling 1,724,740 shares, an increase of 0.2% from the May 15th total of 1,721,104 shares. Based on an average daily trading volume, of 162,241 shares, the short-interest ratio is currently 10.6 days. Currently, 2.3% of the shares of the company are short sold.
Who are some of Matinas BioPharma's key competitors?
Some companies that are related to Matinas BioPharma include BioTime (BTX), Resverlogix (RVX), 22nd Century Group (XXII), Protalix Biotherapeutics (PLX), Neptune Technologies & Bioressources (NEPT), Monash IVF Group (MVF), ABcann Global (ABCN), Horizon Discovery Group (HZD), IMV (IMV), Faron Pharmaceuticals Oy (FARN), Bionomics (BNO), Fennec Pharmaceuticals (FRX), ImmunoVaccine (IMMVF), Arix Bioscience (ARIX) and Mereo BioPharma Group (MPH).
Who are Matinas BioPharma's key executives?
Matinas BioPharma's management team includes the folowing people:
- Mr. Jerome D. Jabbour J.D., Co-Founder, CEO, Pres & Director (Age 44)
- Mr. Dominick M. DiPaolo, Sr. VP of Quality & Regulatory Compliance (Age 42)
- Mr. Gary Gaglione CPA, VP of Fin. & Accounting and Acting CFO (Age 65)
- Dr. Raphael J. Mannino, Sr. VP & Chief Scientific Officer (Age 71)
Has Matinas BioPharma been receiving favorable news coverage?
News stories about MTNB stock have trended somewhat positive this week, Accern Sentiment reports. The research group ranks the sentiment of news coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Matinas BioPharma earned a news sentiment score of 0.08 on Accern's scale. They also gave news headlines about the company an impact score of 47.03 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company's share price in the near future.
Who are Matinas BioPharma's major shareholders?
Matinas BioPharma's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Royal Bank of Canada (0.84%). Company insiders that own Matinas BioPharma stock include Adam K Stern, James S Scibetta and Roelof Rongen. View Institutional Ownership Trends for Matinas BioPharma.
Which major investors are buying Matinas BioPharma stock?
MTNB stock was bought by a variety of institutional investors in the last quarter, including Royal Bank of Canada. Company insiders that have bought Matinas BioPharma stock in the last two years include Adam K Stern, James S Scibetta and Roelof Rongen. View Insider Buying and Selling for Matinas BioPharma.
How do I buy shares of Matinas BioPharma?
Shares of MTNB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Matinas BioPharma's stock price today?
One share of MTNB stock can currently be purchased for approximately $0.55.
How big of a company is Matinas BioPharma?
Matinas BioPharma has a market capitalization of $96.67 million.
How can I contact Matinas BioPharma?
Matinas BioPharma's mailing address is SUITE 302, 1545 ROUTE 206 SOUTH, BEDMINSTER, NJ 7921, United States. The company can be reached via phone at +1-908-4431860.
MarketBeat Community Rating for Matinas BioPharma (MTNB)MarketBeat's community ratings are surveys of what our community members think about Matinas BioPharma and other stocks. Vote "Outperform" if you believe MTNB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MTNB will underperform the S&P 500 over the long term. You may vote once every thirty days.